Takeda Seeks Diabetes, Other Lifestyle Drugs To Supplant Actos Loss
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals says it is looking to drugs for diabetes and other lifestyle diseases to drive sales to replace losses due to generic competition for its Actos (pioglitazone) diabetes drug